Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology developer Cynata Therapeutics (CYP) has raised $15 million through an institutional placement
  • Proceeds will be used to fund the expansion of Cynata’s clinical development pipeline, enhance process development and further regulatory strategy
  • The $15 million institutional placement was offered to new and new investors at 70 cents per new share
  • Healthcare investment firm BioScience Managers led the placement, subscribing to $10 million worth of shares
  • Shares are trading at 75 cents each, down 4.46 per cent following the announcement

Biotechnology developer Cynata Therapeutics (CYP) has raised $15 million through an institutional placement.

Proceeds will be primarily used to fund the expansion of Cynata’s clinical development pipeline, process development and further regulatory strategy.

More specifically, Cynata will undertake further clinical trial designs on multiple unmet medical needs and conditions including, idiopathic pulmonary fibrosis, renal transplantation and diabetic foot ulcers.

The $15 million institutional placement was offered to new and new investors at $0.70 per new share.

A one-for-15 $5.5 million non-renounceable pro-rata entitlement offer will also be offered to eligible shareholders following the placement.

New shares will be allotted December 21.

Cynata Chief Executive and Managing Director Dr Ross Macdonald says the endorsement from BioScience Managers provides validation for the platform.

"The capital secured will enable a logical and significant expansion of our clinical development into new indications, essentially doubling the size of our clinical pipeline," he commented.

"We look forward to initiating the planned studies in the near term and building on the significant progress made to date with the development of our Cymerus platform technology."

Shares are trading at 75 cents each, down 4.46 per cent following the announcement.

CYP by the numbers
More From The Market Herald
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong (centre-left) - The Market Herald

" Imugene (ASX:IMU) increases loss, ramps up trials and research

Imugene (IMU) has ended the half-year with a $6 million loss after increasing its spending on clinical trials and research.
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) pockets $830K R&D rebate

Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive.
Palla Pharma (ASX:PAL) - Departing CEO, Jarrod Ritchie - The Market Herald

" Palla Pharma (ASX:PAL) to raise $18M to reduce debt

Palla Pharma (PAL) has announced plans to tap investors and shareholders for an extra $18 million in capital via a fundraise.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) declares outstanding half-year revenue growth

Incannex Healthcare (IHL) has reported a revenue growth of 11,859 per cent to $1.23 million for the six months to December 31, 2020.